Study Description
The purpose of the core phase of the trial is to assess the efficacy, safety and tolerability of remibrutinib (LOU064) 25 milligrams (mg) twice a day (b.i.d.) over placebo for 24 weeks and in comparison to omalizumab 300 mg every 4 weeks (q4w) for 52 weeks in participants with chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines (H1-AH).
The purpose of the open-label extension phase is to assess efficacy, safety and tolerability up to two years for patients treated with remibrutinib and patients transitioned from omalizumab to remibrutinib at Week 52. In the extension phase, treatment will be with remibrutinib only (i.e., no background therapy). The extension phase will also fulfill the Novartis commitment to provide post-trial access to participants of the previous core phase. The study consists of 4 periods, and the total study duration is up to 112 weeks. Approximately 468 adult participants with CSU are expected to be randomized in the study.
Screening period: A screening period of up to 4 weeks will allow for the assessment of eligibility, determination of baseline disease activity and wash-out of prohibited medications.
Core Phase Treatment Period (52 weeks):
The treatment period will be double-dummy and double-blind, with placebo injections matching omalizumab 300 mg s.c. given to participants in the remibrutinib arm and placebo tablets matching remibrutinib 25 mg given to participants in the omalizumab arm (double-dummy). At the randomization visit, eligible participants will be randomized to one of four treatment arms.
Extension Phase Treatment Period (52 weeks): Optional open-label extension where patients receive treatment with open-label remibrutinib 25 mg, for 52 weeks.
Follow-up period:
For patients that do not enter the extension phase, there will be a 16-week, treatment-free, safety follow-up period.
Patients that enter extension phase will have a 4-week treatment-free safety follow-up period at the end of the extension phase.
All participants will be on a stable, local label-approved standard dose of a second-generation H1-AH ("background therapy") throughout the entire core phase (starting a minimum of 7 days prior to randomization until the end of the core phase).
In addition, to treat unbearable symptoms of CSU flare-ups, participants will be allowed to use a different second-generation H1-AH on an as-needed basis ("rescue therapy").
Interventions
Omalizumab
Placebo to omalizumab
Placebo to remibrutinib
Remibrutinib
Eligibility Criteria
Inclusion Criteria:
* Male and female adult participants ≥18 years of age at the time of signing the informed consent.
* CSU duration for ≥ 6 months prior to screening.
* Diagnosis of CSU inadequately controlled by second generation H1-AH at the time of randomization, defined as:
* The presence of itch and hives for ≥6 consecutive weeks prior to screening, despite the use of second-generation H1-AH during this time period.
* UAS7 score (range 0-42) ≥16, ISS7 score (range 0-21) ≥ 6 and HSS7 score (range 0- 21) ≥ 6 during the 7 days prior to randomization (Day 1).
* Documentation of hives within three months before randomization.
* Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol.
* Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1).
Exclusion Criteria:
* Prior exposure to ligelizumab, omalizumab and other biologics with any effect in CSU, including anti-IgE therapies.
* Significant bleeding risk or coagulation disorders.
* History of gastrointestinal bleeding.
* Requirement for anti-platelet or anti-coagulant medication.
* History or current hepatic disease.
* Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
* Evidence of helminthic parasitic infection as evidenced by stools being positive for a pathogenic organism according to local guidelines.
* Documented history of anaphylaxis.
* Pregnant or nursing (lactating) women.
Novartis Investigative Site
Recruiting
Caba,Buenos Aires,C1414aif,Argentina
Novartis Investigative Site
Recruiting
Rosario,Santa Fe,S2000dbs,Argentina
Novartis Investigative Site
Recruiting
Bahia Blanca,B8000jrb,Argentina
Novartis Investigative Site
Recruiting
Caba,C1012aay,Argentina
Novartis Investigative Site
Recruiting
Capital Federal,C1023aab,Argentina
Novartis Investigative Site
Recruiting
Mendoza,5500,Argentina
Novartis Investigative Site
Recruiting
Woolloongabba,Queensland,4102,Australia
Novartis Investigative Site
Recruiting
Melbourne,Victoria,3004,Australia
Novartis Investigative Site
Recruiting
Porto Alegre,RS,90560 030,Brazil
Novartis Investigative Site
Recruiting
Alphaville Barueri,Sao Paulo,06454010,Brazil
Novartis Investigative Site
Recruiting
Santo Andre,SP,09060-870,Brazil
Novartis Investigative Site
Recruiting
Sorocaba,SP,18040-425,Brazil
Novartis Investigative Site
Recruiting
Sofia,1431,Bulgaria
Novartis Investigative Site
Recruiting
Varna,9000,Bulgaria
Novartis Investigative Site
Recruiting
Sofia,1000,Bulgaria
Novartis Investigative Site
Recruiting
Niagara Falls,Ontario,L2h 1h5,Canada
Novartis Investigative Site
Recruiting
Verdun,Quebec,H4g 3e7,Canada
Novartis Investigative Site
Recruiting
Quebec,G1v 4w2,Canada
Novartis Investigative Site
Recruiting
Edmonton,Alberta,T6g 1c3,Canada
Novartis Investigative Site
Recruiting
Hamilton,Ontario,L8l 3c3,Canada
Novartis Investigative Site
Recruiting
Hamilton,Ontario,L8s 1g5,Canada
Novartis Investigative Site
Recruiting
London,Ontario,N6h 5l5,Canada
Novartis Investigative Site
Recruiting
Brno,Czech Republic,656 91,Czechia
Novartis Investigative Site
Recruiting
Plzen Bolevec,32300,Czechia
Novartis Investigative Site
Recruiting
Praha 10,100 34,Czechia
Novartis Investigative Site
Recruiting
Grenoble,38043,France
Novartis Investigative Site
Recruiting
Clermont Ferrand,63003,France
Novartis Investigative Site
Recruiting
La Rochelle,17019,France
Novartis Investigative Site
Recruiting
Nantes Cedex 1,44093,France
Novartis Investigative Site
Recruiting
Nice,06000,France
Novartis Investigative Site
Recruiting
Pierre Benite,69495,France
Novartis Investigative Site
Recruiting
Toulon Cedex 9,Val De Marne,83800,France
Novartis Investigative Site
Recruiting
Rouen,76031,France
Novartis Investigative Site
Recruiting
Bobigny Cedex,93009,France
Novartis Investigative Site
Recruiting
Freiburg,79106,Germany
Novartis Investigative Site
Recruiting
Bad Bentheim,48455,Germany
Novartis Investigative Site
Recruiting
Muenchen,80377,Germany
Novartis Investigative Site
Recruiting
Gottingen,37075,Germany
Novartis Investigative Site
Recruiting
Halle S,06120,Germany
Novartis Investigative Site
Recruiting
Berlin,13353,Germany
Novartis Investigative Site
Recruiting
Muenchen,81377,Germany
Novartis Investigative Site
Recruiting
Hamburg,22391,Germany
Novartis Investigative Site
Recruiting
Bochum,44791,Germany
Novartis Investigative Site
Recruiting
Muenster,48149,Germany
Novartis Investigative Site
Recruiting
Heidelberg,69120,Germany
Novartis Investigative Site
Recruiting
Bochum,44793,Germany
Novartis Investigative Site
Recruiting
Osnabrueck,49074,Germany
Novartis Investigative Site
Recruiting
Leipzig,04103,Germany
Novartis Investigative Site
Recruiting
Dresden,01307,Germany
Novartis Investigative Site
Recruiting
Stade,21682,Germany
Novartis Investigative Site
Recruiting
Luebeck,23538,Germany
Novartis Investigative Site
Recruiting
Frankfurt,60590,Germany
Novartis Investigative Site
Recruiting
Tuebingen,72076,Germany
Novartis Investigative Site
Recruiting
Mainz,55131,Germany
Novartis Investigative Site
Recruiting
Debrecen,4032,Hungary
Novartis Investigative Site
Recruiting
Kaposvar,7400,Hungary
Novartis Investigative Site
Recruiting
Pecs,7623,Hungary
Novartis Investigative Site
Recruiting
Nagpur,Maharashtra,440015,India
Novartis Investigative Site
Recruiting
Nashik,Maharashtra,422101,India
Novartis Investigative Site
Recruiting
Belgavi,590010,India
Novartis Investigative Site
Recruiting
Bikaner,Rajasthan,334003,India
Novartis Investigative Site
Recruiting
Ahmedabad,Gujarat,380016,India
Novartis Investigative Site
Recruiting
Hyderabad,Telangana,500004,India
Novartis Investigative Site
Recruiting
Bangalore,Karnataka,560004,India
Novartis Investigative Site
Recruiting
Dehradun,Uttarakhand,248001,India
Novartis Investigative Site
Recruiting
Mysore,Karnataka,570001,India
Novartis Investigative Site
Recruiting
New Delhi,110029,India
Novartis Investigative Site
Recruiting
Nagpur,Maharashtra,440012,India
Novartis Investigative Site
Recruiting
Milano,MI,20122,Italy
Novartis Investigative Site
Recruiting
Rozzano,MI,20089,Italy
Novartis Investigative Site
Recruiting
Roma,RM,00168,Italy
Novartis Investigative Site
Recruiting
Ansan,Gyeonggi Do,425-801,Korea, Republic of
Novartis Investigative Site
Recruiting
Busan,49241,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03722,Korea, Republic of
Novartis Investigative Site
Recruiting
Petaling Jaya,Selangor Darul Ehsan,46150,Malaysia
Novartis Investigative Site
Recruiting
Kuala Lumpur,Wilayah Persekutuan,50586,Malaysia
Novartis Investigative Site
Recruiting
Kuala Lumpur,59100,Malaysia
Novartis Investigative Site
Recruiting
Wilayah Persekutuan,62502,Malaysia
Novartis Investigative Site
Recruiting
Pulau Pinang,10990,Malaysia
Novartis Investigative Site
Recruiting
Muar,Johor,84000,Malaysia
Novartis Investigative Site
Recruiting
Ipoh,Perak,30450,Malaysia
Novartis Investigative Site
Recruiting
Villahermosa,Tabasco,86035,Mexico
Novartis Investigative Site
Recruiting
Utrecht,3584 cx,Netherlands
Novartis Investigative Site
Recruiting
Amsterdam,1105 az,Netherlands
Novartis Investigative Site
Recruiting
Gdansk,80 952,Poland
Novartis Investigative Site
Recruiting
Gdansk,80-546,Poland
Novartis Investigative Site
Recruiting
Krosno,38-400,Poland
Novartis Investigative Site
Recruiting
Poznan,60-823,Poland
Novartis Investigative Site
Recruiting
Warszawa,02-507,Poland
Novartis Investigative Site
Recruiting
Bardejov,08501,Slovakia
Novartis Investigative Site
Recruiting
Kezmarok,060 01,Slovakia
Novartis Investigative Site
Recruiting
Svidnik,08901,Slovakia
Novartis Investigative Site
Recruiting
Trnava,91702,Slovakia
Novartis Investigative Site
Recruiting
Valencia,46026,Spain
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08035,Spain
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08036,Spain
Novartis Investigative Site
Recruiting
Valencia,Comunidad Valenciana,46015,Spain
Novartis Investigative Site
Recruiting
Pozuelo de Alarcon,Madrid,28223,Spain
Novartis Investigative Site
Recruiting
Cordoba,Andalucia,14004,Spain
Novartis Investigative Site
Recruiting
Las Palmas de Gran Canaria,35010,Spain
Novartis Investigative Site
Recruiting
Granada,Andalucia,18014,Spain
Novartis Investigative Site
Recruiting
Madrid,28046,Spain
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08003,Spain
Novartis Investigative Site
Recruiting
Geneve 14,1211,Switzerland
Novartis Investigative Site
Recruiting
St Gallen,9007,Switzerland
Novartis Investigative Site
Recruiting
Zuerich,8006,Switzerland
Novartis Investigative Site
Recruiting
Zuerich,8091,Switzerland
Novartis Investigative Site
Recruiting
Taipei,10002,Taiwan
Novartis Investigative Site
Recruiting
Taoyuan,33305,Taiwan
Novartis Investigative Site
Recruiting
Bangkoknoi,Bangkok,10700,Thailand
Novartis Investigative Site
Recruiting
Songkhla,Hat Yai,90110,Thailand
Novartis Investigative Site
Recruiting
Khon Kaen,THA,40002,Thailand
Novartis Investigative Site
Recruiting
Bangkok,10400,Thailand
Novartis Investigative Site
Recruiting
Chiang Mai,50200,Thailand
Novartis Investigative Site
Recruiting
Aydin,09100,Turkey
Novartis Investigative Site
Recruiting
Denizli,20070,Turkey
Novartis Investigative Site
Recruiting
Fatih-Istanbul,34093,Turkey
Novartis Investigative Site
Recruiting
Sakarya,54290,Turkey
Novartis Investigative Site
Recruiting
Istanbul,TUR,34098,Turkey
Novartis Investigative Site
Recruiting
Birmingham,B9 5ss,United Kingdom
Novartis Investigative Site
Recruiting
Westbruy On Trym,Bristol,Bs10 5nb,United Kingdom
Novartis Investigative Site
Recruiting
Leeds,West Yorkshire,Ls9 7tf,United Kingdom
Novartis Investigative Site
Recruiting
Oxford,Ox3 7le,United Kingdom
Novartis Investigative Site
Recruiting
Hanoi,100000,Vietnam
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.